8:30 am Chair’s Opening Remarks
TIL- Growth & Modification
8:45 am Investigating TIL’s TCR Repertoire & Strategies for Their Isolation
9:10 am Enhancing the Function of Tumor-Specific T-Cells Through the Expression of Co-Stimulatory Chimeric Switch Receptors (CSR)
Synopsis
- Explaining the importance of co-stimulatory signals in T-cells
- Recalling the possibility to improve patient T-cells function through the manipulation of co-stimulatory pathways
- Detailing the basics of design and use of co-stimulatory chimeric switch receptors to convert inhibitory signals into activation one
9:35 am Understanding the Landscape of Neoantigen Targeting in TIL Therapy
Synopsis
• Comparing the frequency of neo-antigen-specific and tumorreactive
TILs in situ and after in vitro expansion
• Forecasting the fate of suboptimal in-vitro expansion of clinicallyrelevant
TILs
• Describing transcriptomic signatures driving cell persistence and
tumor infiltration post ACT.
10:00 am TIL- Growth and Modification Q&A + Open Counsel
10:15 am Morning Refreshments & Speed Networking
Synopsis
Virtual Speed Networking
Recreating the face-to-face networking in the virtual
world. We will pair you up with fellow attendees to break
the ice and make new business relationships!
Morning Networking
• Explore Demo Area and Virtual Booths
• 1-1 Meetings
Clinical TIL Treatment: Addressing the Combination, Order & Impact of Therapeutic Approaches
10:45 am PANEL: Combinational Approaches with TIL therapy
Synopsis
- Comparing methodologies to treat solid tumors with various combinatory approaches to improve TIL
efficacy - Discussing the order and dosing procedures for alternative approaches
- Considering the various ways of modifying TILs
11:15 am Investigating the Impact of Various Lymphodepleting Regiments Prior to TIL Therapy
Synopsis
- Exploring the clinical preconditioning required before treatment.
- Describing the bone marrow ablation, recovery and toxicity of
treatment options
11:40 am TILT -123 in Phase 1 Clinical Trials. Concurrent TIL & Oncolytic Viral Therapy.
Synopsis
- Interpreting current clinical evidence and extrapolating the benefits
- Describing mechanistic action of oncolytic virus
- Considering changes in the tumor microenvironment and TIL response
from viral treatment
12:05 pm Maximizing TIL Efficacy: Where to Position TIL Therapy
Synopsis
- Addressing the current melanoma treatment landscape and the
stage which TILs are best used. - Reviewing TIL activity before and after checkpoint inhibitors
12:30 pm Clinical TIL Treatment: Addressing the Combination, Order & Impact of Therapeutic Approaches Q&A + Open Counsel
12:45 pm Networking Lunch
Synopsis
- Explore Demo Area and Virtual Booths
Manufacturing & Operational Challenges
1:45 pm Streamlining TIL Therapy for Melanoma Treatment.
Synopsis
- Adapting the process of growing TIL for robust expansion of TIL from any tumor type
- Functional improvement of TIL through TGF-β signalling blockade
- Clinical effectiveness of TIL
2:10 pm Iovance – advancing Advancing TIL Towards Commercialization
Synopsis
- Delving into Iovance’s commercial success in the market
- Sharing information regarding the four products in phase 2 trials.
2:35 pm Manufacturing & Operational Challenges Q&A + Open Counsel
2:45 pm Afternoon Networking
Synopsis
- Explore Demo Area and Virtual Booths
3:15 pm PANEL: Discussing Other TIL Therapy Tumor Targets
Synopsis
- Comparing research from various tumor target locations
- Sharing various challenges specific to each tumor region
- Collaborating in methods of overcoming diminished TIL products from certain cancer sites.
3:45 pm The Moffit Centre: TIL therapy in Clinical Care: Integrating Product to Patient
Synopsis
- Providing a pragmatic overview of clinical care
- Divulging in the therapeutic contrasts for solid tumor treatments, including CAR-T and TCR therapy
- Detailing their methodology for TIL identification and expansion strategy
4:15 pm Cooperative Q&A + Open Counsel with Moffit Cancer Center
4:30 pm Last networking opportunity.
4:45 pm Adoptive T cell Therapy at the Princess Margaret Cancer Centre
Synopsis
- Describing adoptive T cell therapy trials with in-house cell manufacturing
- Describing work in melanoma and solid tumors
5:15 pm CRISPR/Cas9-Engineered Tumor Infiltrating Lymphocyte (eTILTM) Therapies for Solid Tumors
Synopsis
- Systematic identification of genes restoring and amplifying T cell
function in the tumor microenvironment - Divulging updates on KSQ-001 and next generation TIL approaches
- Lessons learnt from the use of CRISPR/Cas9 for T cell rejuvenation
and enhanced stability within the tumor microenvironment
5:40 pm Humanized TIL/PDX Models to Study Patient-Specific Response to Immunotherapy
Synopsis
- Providing examples and techniques of modelling use for patient
xenograph models - Detailing cell culture and rapid expansion growth models with IL factors
- Evaluation of patient-specific response to immune checkpoint inhibitors
6:05 pm TIL therapies: At the cellular level Q&A + Open Counsel
6:15 pm Chair’s Closing Remarks
6:30 pm End of Day
